ICR research showcased in major new Science Museum gallery documenting history of medicine 29 Jan 2020 The Science Museum's new £24 million medicine galleries showcases pioneering research from The Institute of Cancer Research, London, as part of its story of modern medicine. Find out more Show/Hide
Olaparib becomes first gene-targeted medicine to show benefits in prostate cancer 02 Dec 2019 A pioneering precision medicine already licensed for breast and ovarian cancer can also slow or stop tumour growth in some men with advanced prostate cancer, a new clinical trial shows. Find out more Show/Hide
ESMO 2019: Breast and ovarian cancer drug outperforms targeted hormone therapy in some men with advanced prostate cancer 30 Sep 2019 A drug used for breast and ovarian cancer is more effective than modern targeted hormone treatments at slowing progression and improving survival in some men with advanced prostate cancer, phase III clinical trial findings reveal. Find out more Show/Hide
ICR calls for wider gene testing in ovarian cancer after approval of olaparib earlier in treatment for women with BRCA mutations 26 Jul 2019
ASCO 2019: Breast cancer drug effective in 80 per cent of men with BRCA-mutant prostate cancer 05 Jun 2019
The ICR responds to the FDA approval of talazoparib for women with BRCA-mutant advanced breast cancer 18 Oct 2018